PMID- 12397367
OWN - NLM
STAT- MEDLINE
DCOM- 20021122
LR  - 20191106
IS  - 0897-5957 (Print)
IS  - 0897-5957 (Linking)
VI  - 20
IP  - 3
DP  - 2002 Fall
TI  - The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
PG  - 199-216
AB  - Standard unfractionated heparin (UFH) has been in clinical use for over 50 years. 
      The commercial use of low molecular weight heparins (LMWHs) began in the mid 
      1980s for hemodialysis and the prophylaxis of deep vein thrombosis (DVT). 
      Initially, the clinical development of LMWHs was concentrated on the European 
      continent. Subsequently, LMWHs were introduced in North America as well. In the 
      initial stages of development of these drugs only nadroparin, dalteparin and 
      enoxaparin were used. Subsequently, several other LMWHs such as ardeparin, 
      tinzaparin, reviparin and parnaparin were introduced. LMWHs constitute a group of 
      important medications with total sales reaching nearly 2.5 billion dollars with 
      expanded indications reaching far beyond the initial indications for the 
      prophylaxis of post-surgical DVT. This review highlights the pharmacology of 
      tinzaparin. Unlike other LMWHs, tinzaparin is prepared by enzymatic hydrolysis 
      with heparinase, while various chemical depolymerization methods are used for the 
      synthesis of other LMWHs. As compared with the standard heparin, LMWHs have 
      different pharmacodynamic, and pharmacokinetic properties; they also differ in 
      clinical benefits.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208-3492, USA. 
      mousas@acp.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cardiovasc Drug Rev
JT  - Cardiovascular drug reviews
JID - 9006912
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 7UQ7X4Y489 (Tinzaparin)
SB  - IM
MH  - Anticoagulants/*pharmacology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/*pharmacology/*therapeutic use
MH  - Humans
MH  - Tinzaparin
MH  - Treatment Outcome
MH  - United States
MH  - Venous Thrombosis/*drug therapy
RF  - 63
EDAT- 2002/10/25 04:00
MHDA- 2002/11/26 04:00
CRDT- 2002/10/25 04:00
PHST- 2002/10/25 04:00 [pubmed]
PHST- 2002/11/26 04:00 [medline]
PHST- 2002/10/25 04:00 [entrez]
AID - 10.1111/j.1527-3466.2002.tb00087.x [doi]
PST - ppublish
SO  - Cardiovasc Drug Rev. 2002 Fall;20(3):199-216. doi: 
      10.1111/j.1527-3466.2002.tb00087.x.